C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 221/20 (2006.01) C07D 221/10 (2006.01) C07D 401/12 (2006.01) C07D 405/12 (2006.01) C07D 409/12 (2006.01) C07D 471/04 (2006.01) C07D 487/04 (2006.01) C07D 498/04 (2006.01) C07D 513/04 (2006.01)
Patent
CA 2251989
Disclosed are compounds of formula (I) or the pharmaceutically acceptable acid addition salts thereof wherein: R1-R4 represent organic or inorganic groups; A represents an alkylene group of 2 to 6 carbon atoms optionally substituted with one or more alkyl groups having from 1 to 4 carbon atoms; Y represents methylene, oxygene, sulfur, or NH; and X is either N, C or CH, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.
L'invention concerne des composés de formule (I) ou les sels d'addition d'acide de ceux-ci, acceptables sur la plan pharmaceutique. Dans la formule (I), R¿1?-R¿4? représentent des groupes organiques ou inorganiques; A représente un groupe alkylène à 2 à 6 atomes de carbone éventuellement substitué par un ou plusieurs groupes alkyle à 1 à 4 atomes de carbone; Y représente méthylène, oxygène, soufre ou NH; et X représente N, C ou CH. Lesdits composés sont utiles dans le traitement de troubles affectifs tels que la schizophrénie, la dépression, la maladie d'Alzheimer, les troubles moteurs tels que le parkinsonisme et la dystonie et d'autres troubles qui répondent au blocage dopaminergique tel que la pharmacodépendance les troubles obsessionnels impulsifs. De plus, les composés selon l'invention peuvent être utiles dans le traitement des effets secondaires extrapyramidaux associés à l'utilisation d'agents neuroleptiques.
Chen Xi
Thurkauf Andrew
Yuan Jun
Mbm & Co.
Neurogen Corporation
LandOfFree
Tricyclic aminoalkylcarboxamides; novel dopamine d3 receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic aminoalkylcarboxamides; novel dopamine d3 receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic aminoalkylcarboxamides; novel dopamine d3 receptor... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1348414